Analyzing Bio-Rad Laboratories (NYSE:BIO.B) and Akoya Biosciences (NASDAQ:AKYA)

Bio-Rad Laboratories (NYSE:BIO.B) and Akoya Biosciences (NASDAQ:AKYA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Valuation & Earnings

This table compares Bio-Rad Laboratories and Akoya Biosciences’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Rad Laboratories $2.55 billion 9.22 $3.81 billion N/A N/A
Akoya Biosciences $42.44 million 12.59 -$16.71 million N/A N/A

Bio-Rad Laboratories has higher revenue and earnings than Akoya Biosciences.

Analyst Ratings

This is a summary of current ratings for Bio-Rad Laboratories and Akoya Biosciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories 0 0 0 0 N/A
Akoya Biosciences 0 0 4 0 3.00

Akoya Biosciences has a consensus price target of $25.50, indicating a potential upside of 77.33%. Given Akoya Biosciences’ higher probable upside, analysts plainly believe Akoya Biosciences is more favorable than Bio-Rad Laboratories.

Profitability

This table compares Bio-Rad Laboratories and Akoya Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories 140.48% 4.65% 3.52%
Akoya Biosciences N/A N/A N/A

Insider & Institutional Ownership

0.4% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 26.9% of Akoya Biosciences shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Bio-Rad Laboratories beats Akoya Biosciences on 6 of the 10 factors compared between the two stocks.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

About Akoya Biosciences

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. The company offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. It provides two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational, and clinical research. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.